NRXS Stock Forecast: NeurAxis, Inc. Price Predictions for 2026-2027
The median 12-month analyst price target for NeurAxis, Inc. is $11. Ticker Nerd's systematic factor model, run across ~4,300 US stocks, ranks it 47 of 100 as at 21 Nov 2026 — in the lower half.
One number for the whole business
Consensus tells you what everyone already believes. The model scores NeurAxis, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,300 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Momentum (84): The shares have been drifting up relative to others.
Revisions (31): Analysts have, on balance, been cutting their forecasts.
Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.
NRXS stock forecast 2026-2027: analyst price targets & predictions
The bullish and bearish analyst opinions on NRXS, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 20 Mar 2026 | Craig-Hallum | Maintains | Buy | — |
| 22 Dec 2025 | Craig-Hallum | Maintains | Buy | — |
| 16 June 2025 | Craig-Hallum | Initiates | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Wall Street targets run 12 to 18 months out. No analyst publishes a 2030 price target for NRXS.
This page is one stock. Monday covers all of them.
NRXS appears in the Radar on the weeks it earns a place.
- Market Radar, every Monday: the week's biggest rank moves across ~4,300 US stocks, and the reason for each.
- The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.
AI cloud capacity
MSFTAMZNGOOGLORCL
AI chips
NVDAAVGOAMDMU
AI networking and servers
ANETDELLLITECRDO
Data centre power
VRTCEGGEVVST
NRXS vs the S&P 500
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 20 Nov 2026, NeurAxis, Inc. returned +68.1% against +6.9% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
NRXS analyst estimate revisions
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
Financials
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
- Trailing P/E
- —
- Price / sales
- 9.8×
- Price / book
- 17.2×
- EV / EBITDA
- —
Cheaper than 12% of US stocks
Cheaper than 4% of US stocks
- Revenue growth (YoY)
- —
- Earnings growth (YoY)
- —
- Gross margin
- 85.9%
- Operating margin
- —
- Net margin
- —
Higher than 94% of US stocks
- Return on equity
- −409.7%
- Return on assets
- −122.3%
- Dividend yield
- —
Higher than 3% of US stocks
Higher than 2% of US stocks
Bars mark the percentile across the ~4,300 US stocks Ticker Nerd covers, among those reporting the figure.
Key statistics
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
NeurAxis, Inc. has a market value of $63.9M and an enterprise value of $59.8M.
Revenue in the twelve months to 30 June 2026: $5.3M. The latest quarter grew 115.7% year on year.
Net income over the same four quarters: −$7.7M, a −144.4% net margin.
Free cash flow in the twelve months to 30 June 2026: −$5.7M.
NeurAxis, Inc. employs 24 people — $222K of revenue per employee.
Data provided by Twelve Data
NRXS and its peers
The nearest names by industry and size, scored by the same model — like for like.
Take a look at NRXS’s peer groups, ranked by the model: healthcare stocks · biotech stocks.
Look up any of the roughly 4,300 stocks we score.
The rank is the raw material. Whether the rules would actually own NeurAxis, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Questions about NRXS
What is the NRXS stock price forecast for 2026-2027?
The median 12-month analyst price target for NeurAxis, Inc. is $11, with estimates ranging from $9 to $13. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Is NRXS stock a buy right now?
Of the 2 analysts covering NeurAxis, Inc., 2 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks NeurAxis, Inc. 47 out of 100 across roughly 4,300 US stocks as at 21 Nov 2026. None of this is personal advice — it does not consider your circumstances.
How does Ticker Nerd's model rank NRXS?
As at 21 Nov 2026, NeurAxis, Inc. ranks 47 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,300 US stocks, built from its factor families. Its strongest factor family is Momentum (84 of 100).
Will NRXS stock go up?
No one can know that. What the data says: the median 12-month target from 2 analysts is $11, and Ticker Nerd's factor model ranks NeurAxis, Inc. 47 out of 100 as at 21 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
What is the NRXS stock forecast for 2030?
No analyst covering NeurAxis, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for NRXS are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $9 to $13 over the next 12 months.
How has NRXS stock performed over the past year?
NeurAxis, Inc. returned +68.1% over the 12 months to 20 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.
What does NeurAxis, Inc. do?
NeurAxis, Inc. is a medical technology company focused on neuromodulation therapies for chronic and debilitating conditions, with an emphasis on disorders of the gut-brain interaction. Its current product portfolio centers on IB-Stim, a drug-free, non-surgical device worn behind the ear and designed to deliver percutaneous electrical nerve field stimulation for patients with functional abdominal pain associated with irritable bowel syndrome, functional dyspepsia, and related nausea symptoms.
About NeurAxis, Inc.
NeurAxis, Inc. is a medical technology company focused on neuromodulation therapies for chronic and debilitating conditions, with an emphasis on disorders of the gut-brain interaction. Its current product portfolio centers on IB-Stim, a drug-free, non-surgical device worn behind the ear and designed to deliver percutaneous electrical nerve field stimulation for patients with functional abdominal pain associated with irritable bowel syndrome, functional dyspepsia, and related nausea symptoms. The company serves pediatric and adult patients through healthcare settings such as hospitals and clinics, where its therapies are used to support symptom management in targeted gastrointestinal conditions. NeurAxis also works to commercialize evidence-based devices that address unmet needs in digestive health and related neuromodulation care. Headquartered in Carmel, Indiana, NeurAxis operates as a specialized player in the medical device market with a focus on non-invasive treatment options.
CEO Mr. Brian Carrico · 24 employees · United States · https://neuraxis.com